InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Why India's Novartis ruling is not patent Armageddon

Peter Leung, Hong Kong

The Supreme Court’s denial of Novartis’s Glivec patent has prompted dire warnings about patent protection in India, but practitioners say that the decision was just a straightforward application of the law

The patent in question involved a beta crystalline form of Imatinib Mesylate, a molecule invented in the 1990s with a US patent application from April 1994. The original molecule was not patented in India because under Indian patent law, substances...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null

null null null


November / December 2018

The 50 most influential people in IP

Managing IP reveals our pick of the people driving intellectual property law, policy and business this year. Read the full list here

Most read articles